SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Short Candidates
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tuck who wrote (705)9/13/2004 9:17:02 PM
From: mopgcw  Read Replies (1) of 897
 
GS: Sep 10, 2004 TRMS(IL/N): New CEO appointed, strategic plus A.
Yesterday, Trimeris announced the appointment of Steven D. Skolsky as the new Chief
Executive Officer. Current CEO, Dr. Dani Bolognesi will continue as Chief Scientific
Officer and has been named Vice Chairman of the Board. We believe that the
management change is intended to facilitate the commercial expansion of Fuzeon with
experienced commercial leadership and bolster clinical development where Dr.
Bolognesi will be able to dedicate more efforts. Mr. Skolsky joins from
GlaxoSmithKline, where he was most recently Senior Vice President of Commercial
Strategy. Mr. Skolsky had also been Vice President of Sales and Marketing in the
HIV/Oncology division and has nearly 25 years of pharmaceutical experience. We
maintain our In-Line rating on Trimeris and a Neutral coverage view. The key risk for
the stock is lack of sufficient pick up in Fuzeon sales.

Sep 02, 2004 TRMS(IL/N): Lower to In-Line from Outperform due to lack of
near-term catalysts

B.
With its market cap approximating $260MM and estimated commercial potential of
Fuzeon of between $200-300MM, we continue to believe that Trimeris represents good
value for longer-term oriented investors. However, based on lack of near-term catalysts
relative to other companies under coverage, we are lowering our rating to In-Line from
Outperform within our Neutral coverage view. We maintain our estimates on Trimeris.
While we are enthusiastic about the long-term prospects of Fuzeon, we continue to
expect that it will take time to build the market for Fuzeon. The key risk for the stock is
lack of sufficient pick-up in Fuzeon sales.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News